Fiera Capital (Canada)
KRYS icon

Fiera Capital (Canada)’s Krystal Biotech KRYS Stock Holding History

Fiera Capital (Canada)’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.3M Sell
14,251
-9,895
-41% -$2.96M 0.02% 226
2026
Q1 		$6.24M Buy
24,146
+5,289
+28% +$1.41M 0.02% 236
2025
Q4 		$4.65M Buy
18,857
+3,794
+25% +$799K 0.01% 238
2025
Q3 		$2.66M Sell
15,063
-448
-3% -$67.1K 0.01% 273
2025
Q2 		$2.13M Sell
15,511
-134
-0.9% -$19.7K 0.01% 292
2025
Q1 		$2.82M Sell
15,645
-28
-0.2% -$4.71K 0.01% 276
2024
Q4 		$2.46M Sell
15,673
-527
-3% -$93.5K 0.01% 278
2024
Q3 		$2.95M Sell
16,200
-8
-0% -$1.54K 0.01% 266
2024
Q2 		$2.98M Buy
16,208
+130
+0.8% +$21.8K 0.01% 263
2024
Q1 		$2.86M Buy
16,078
+178
+1% +$24.7K 0.01% 259
2023
Q4 		$1.97M Buy
+15,900
New +$1.76M 0.01% 289

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fiera Capital (Canada)'s KRYS Position: Q2 2026 in Review

Fiera Capital (Canada) reduced its Krystal Biotech (KRYS) stake by 41% in Q2 2026, selling an estimated $2.96M and leaving 14,251 shares worth $5.3M. The position accounts for 0.02% of the portfolio, ranked #226.

Fiera Capital (Canada) first reported a position in KRYS in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.24M in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Fiera Capital (Canada) held 14,251 shares of Krystal Biotech worth $5.3M as of Q2 2026.
  • Fiera Capital (Canada) sold 9,895 Krystal Biotech shares in Q2 2026, an estimated $2.96M.
  • Krystal Biotech made up 0.02% of Fiera Capital (Canada)'s portfolio in Q2 2026, its #226 holding.
  • Fiera Capital (Canada) first reported a position in Krystal Biotech in Q4 2023 and has held it in 11 quarters since.
  • Fiera Capital (Canada)'s Krystal Biotech position peaked at $6.24M in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Fiera Capital (Canada)'s 13F filing for Q2 2026, filed 7 Aug 2026.